RCE — Recce Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- AU$96.88m
- AU$104.60m
- AU$9.94m
Annual cashflow statement for Recce Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | C2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.08 | -1.3 | 0.23 | 0.778 | 0.993 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -9.01 | -12.7 | -13 | -20.4 | -9.89 |
| Capital Expenditures | -0.04 | -0.039 | -0.142 | -0.026 | -0.062 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -0.163 | -0.418 | 0.186 |
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.04 | -0.039 | -0.305 | -0.444 | 0.124 |
| Financing Cash Flow Items | -0.389 | -0.104 | -0.563 | -1.74 | -0.271 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.24 | 2.71 | 16.2 | 26.9 | 2.01 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -9.29 | -10 | 2.85 | 6.03 | -7.75 |